Business Wire

Quectel Expands Mid-tier 5G Portfolio with New RedCap 3GPP Release 17 Variants

2.3.2026 08:00:00 CET | Business Wire | Press release

Share

Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the expansion of its 5G RedCap portfolio with the launch of the RM255C-GL for global markets and the RG255C-NA for the North America market, further strengthening its mid-tier 5G offering for worldwide deployments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260301754857/en/

Quectel expands mid-tier 5G portfolio with new RedCap 3GPP release 17 variants

As 5G expands further into industrial and IoT domains, the need for solutions that combine strong performance with cost efficiency is becoming increasingly critical. Positioned between high-speed eMBB and narrowband NB-IoT, 5G RedCap (Reduced Capability) has emerged as the ideal technology to address this mid-tier connectivity gap. With a comprehensive product portfolio and global deployment expertise, Quectel enables a seamless transition for mid-speed IoT applications moving toward scalable 5G connectivity.

The RM255C-GL is a 5G Sub-6GHz RedCap module in the M.2 form factor, developed in accordance with 3GPP Release 17. It supports peak data rates of up to 223Mbps downlink and 123Mbps uplink, with 5G Sub-6GHz standalone (SA) operation and LTE Cat 4 fallback. Backward compatibility with Release 15 and Release 16 networks ensures smooth deployment across existing infrastructures. Designed for seamless upgrades, the RM255C-GL is pin-to-pin compatible with Quectel’s RM5x0N and RM50xQ 5G series, and both pin-to-pin and size compatible with selected LTE-A and 4G modules including the EM06, EM12 series, EM160R-GL and EM05, simplifying migration from LTE to 5G RedCap.

The module integrates Qualcomm® IZat™ Gen 9VT location technology with optional multi-constellation GNSS support (GPS, GLONASS, BDS, Galileo, QZSS and NavIC), enabling fast, accurate and reliable positioning. With worldwide 5G and LTE coverage, support for 5G SA mode, embedded protocol stacks and high-speed USB 2.0 and PCIe 2.0 interfaces, the RM255C-GL is well suited to a broad range of mid-tier IoT applications.

The RG255C-NA is a 5G RedCap Sub-6GHz LGA module designed in compliance with 3GPP Release 17. Supporting key 5G capabilities including URLLC and network slicing, the module delivers peak data rates of up to 223Mbps downlink and 123Mbps uplink. It operates in 5G Sub-6GHz standalone (SA) mode with LTE Cat 4 fallback and is backward compatible with Release 15 and Release 16 networks, ensuring smooth migration and broad network coverage. Compatible with Quectel’s compact EG2x 4G module series, the RG255C-NA simplifies design upgrades while meeting mid-speed application requirements for higher capacity, low latency, and enhanced reliability in industrial and commercial deployments.

Purpose-built for industrial-grade applications, the RG255C-NA integrates Qualcomm® IZat™ Gen 9VT location technology, supporting multi-constellation GNSS including GPS, GLONASS, NavIC, BDS, QZSS and Galileo. The integrated GNSS receiver streamlines product development while enabling fast, accurate, and dependable positioning. A comprehensive suite of Internet protocols, industry-standard interfaces, including USB 2.0, PCIe 2.0, PCM, UART, SGMII and SPI, along with USB driver support for Windows 10/11, Linux and Android, ensures broad compatibility and flexibility across a wide range of 5G RedCap IoT applications.

"The commercialization of 5G RedCap is a key milestone in making 5G ubiquitous. For a long time, the industry has faced difficult trade-offs between performance and cost. The launch of Quectel's two new RedCap modules aims to solve this core pain point,” commented Leo Yao, Product Director, Quectel Wireless Solutions. “Quectel offers not just a module, but a complete solution including hardware reference designs for application scenarios, external edge computing capabilities, and global certifications, significantly lowering customers' product development barriers and time-to-market."

As 5G adoption accelerates beyond consumer markets into industrial applications, demand is growing for solutions that balance performance with cost and power efficiency. In mid- to high-speed use cases such as Industrial IoT, video surveillance, and wearables, traditional 5G modules can be oversized in cost, power consumption, and form factor, while 4G technologies lack the bandwidth, latency, and long-term roadmap required for future deployments, particularly as LTE sunset plans advance in markets such as the United States. Defined in the 3GPP Release 17 standard, 5G RedCap addresses this gap by streamlining device capabilities to significantly reduce complexity, cost, and energy consumption, while retaining essential 5G features. Positioned between LTE Cat 4/6 and full 5G, RedCap is set to become a key enabler of scalable, industrial-grade 5G adoption.

Across sectors such as energy, mobile broadband, and wearables, 5G RedCap is overcoming the cost and power limitations associated with traditional 5G modules, delivering right-sized connectivity to support large-scale digital transformation. RedCap is well suited to smart grid deployments, delivering the ultra-reliable, low-latency performance utilities require while reducing module complexity and cost. In mobile hotspots and industrial sensor networks, it enables scalable, cost-efficient 5G connectivity, ideal for smart factories with large numbers of connected devices. For wearables such as smartwatches and fitness trackers, RedCap lowers power consumption and module size, supporting compact designs and extended battery life while bringing 5G to next-generation consumer and professional devices.

The RM255C-GL and RG255C-NA have successfully completed the required regulatory and industry conformance certifications, reinforcing their readiness for global deployment. The RG255C-NA is certified to FCC, IC and PTCRB standards, while the RM255C-GL has achieved CE, RCM, FCC, IC, GCF and PTCRB certifications. This comprehensive approval coverage streamlines device certification, reduces time to market and provides customers with confidence in seamless, compliant integration across target regions.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global end-to-end IoT solutions provider backed by outstanding support and services.

With a worldwide team of over 5,800 professionals, we lead the way in delivering end-to-end IoT solutions, spanning cellular, GNSS, satellite, Wi-Fi and Bluetooth modules, high-performance antennas, value-added services and full turnkey offerings including ODM services and system integration.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit www.quectel.com or LinkedIn

View source version on businesswire.com: https://www.businesswire.com/news/home/20260301754857/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye